|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
AR004752A1
(es)
*
|
1995-11-28 |
1999-03-10 |
Schering Corp |
2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
|
|
US5824683A
(en)
*
|
1995-11-28 |
1998-10-20 |
Schering Corporation |
2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
|
US6403799B1
(en)
*
|
1999-10-21 |
2002-06-11 |
Agouron Pharmaceuticals, Inc. |
Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
|
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
ATE395349T1
(de)
*
|
2001-08-28 |
2008-05-15 |
Schering Corp |
Polycyclische guanin phosphodiesterase inhibitoren
|
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
|
JP2005511500A
(ja)
|
2001-08-31 |
2005-04-28 |
ザ ロックフェラー ユニバーシティー |
脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節
|
|
JP2005509038A
(ja)
*
|
2001-11-09 |
2005-04-07 |
シェーリング コーポレイション |
多環式グアニン誘導体ホスホジエステラーゼv阻害剤
|
|
SI1509525T1
(sl)
|
2002-05-31 |
2006-12-31 |
Schering Corp |
Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
|
|
CN1860119A
(zh)
*
|
2003-07-31 |
2006-11-08 |
先灵公司 |
用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
|
|
BRPI0416202A
(pt)
*
|
2003-11-21 |
2006-12-26 |
Schering Corp |
formulações inibidoras de fosfodiesterase v
|
|
SE0401653D0
(sv)
*
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
|
WO2006104870A2
(en)
*
|
2005-03-25 |
2006-10-05 |
Schering Corporation |
Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
|
|
US8273750B2
(en)
*
|
2005-06-06 |
2012-09-25 |
Takeda Pharmaceutical Company Limited |
Organic compounds
|
|
EP1919287A4
(en)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
|
|
AU2006327315A1
(en)
|
2005-12-23 |
2007-06-28 |
Astrazeneca Ab |
Imidazole derivatives for the treatment of gastrointestinal disorders
|
|
AU2006327317B2
(en)
|
2005-12-23 |
2010-11-25 |
Astrazeneca Ab |
GABA-B receptor modulators
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
WO2007143705A2
(en)
*
|
2006-06-06 |
2007-12-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EP2081431B1
(en)
*
|
2006-11-13 |
2013-01-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2008070095A1
(en)
*
|
2006-12-05 |
2008-06-12 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
US7901872B2
(en)
|
2007-05-21 |
2011-03-08 |
Macronix International Co., Ltd. |
Exposure process and photomask set used therein
|
|
CA2691194A1
(en)
*
|
2007-06-21 |
2008-12-31 |
Deen Tulshian |
Polycyclic guanine derivatives and methods of use thereof
|
|
EP2240490B1
(en)
|
2007-12-06 |
2013-09-04 |
Takeda Pharmaceutical Company Limited |
Organic compounds
|
|
US8846693B2
(en)
*
|
2007-12-06 |
2014-09-30 |
Intra-Cellular Therapies, Inc. |
Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
|
|
WO2009144548A1
(en)
*
|
2008-05-28 |
2009-12-03 |
Glenmark Pharmaceuticals S.A. |
Imidazo [2,1-b] purine derivatives as trpa1 modulators
|
|
HUE028347T2
(en)
|
2008-06-10 |
2016-12-28 |
Abbvie Inc |
Tricyclic compounds
|
|
ES2638912T3
(es)
|
2008-12-06 |
2017-10-24 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
|
EP2358204B1
(en)
*
|
2008-12-06 |
2015-08-05 |
Intra-Cellular Therapies, Inc. |
4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
|
|
MA32942B1
(fr)
|
2008-12-06 |
2012-01-02 |
Intra Cellular Therapies Inc |
Composes organiques
|
|
MA32940B1
(fr)
|
2008-12-06 |
2012-01-02 |
Intra Cellular Therapies Inc |
Composes organiques
|
|
JP5710492B2
(ja)
|
2008-12-06 |
2015-04-30 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
US8859564B2
(en)
|
2008-12-06 |
2014-10-14 |
Intra-Cellular Therapies, Inc. |
Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1
|
|
US11464781B2
(en)
|
2009-02-25 |
2022-10-11 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitors for ophthalmic disorders
|
|
US9468637B2
(en)
|
2009-05-13 |
2016-10-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
|
US8785639B2
(en)
|
2009-12-01 |
2014-07-22 |
Abbvie Inc. |
Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
|
|
PH12012501076B1
(en)
|
2009-12-01 |
2018-07-04 |
Abbvie Inc |
Novel tricyclic compounds
|
|
WO2011153138A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EP2575817A4
(en)
|
2010-05-31 |
2014-01-08 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
|
WO2011153135A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
EP2956141A4
(en)
|
2013-02-17 |
2016-10-26 |
Intra Cellular Therapies Inc |
NEW USES
|
|
WO2014145617A2
(en)
|
2013-03-15 |
2014-09-18 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
AU2014234990B2
(en)
|
2013-03-15 |
2017-11-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
JP6696904B2
(ja)
|
2014-01-08 |
2020-05-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
製剤および医薬組成物
|
|
US9884872B2
(en)
|
2014-06-20 |
2018-02-06 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
|
EP3177627B1
(en)
|
2014-08-07 |
2019-07-24 |
Intra-Cellular Therapies, Inc. |
Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
ES2915200T3
(es)
|
2014-09-17 |
2022-06-21 |
Intra Cellular Therapies Inc |
Derivados de 7,8-dihidro-[2H]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5H)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
|
|
CA2969597C
(en)
|
2014-12-06 |
2023-10-24 |
Intra-Cellular Therapies, Inc. |
1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors
|
|
CA2969594A1
(en)
|
2014-12-06 |
2016-06-09 |
Intra-Cellular Therapies, Inc. |
Pde2 inhibiting organic compounds
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
CN120483986A
(zh)
|
2015-10-16 |
2025-08-15 |
艾伯维公司 |
制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
|
|
JP2019510039A
(ja)
|
2016-03-28 |
2019-04-11 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規組成物および方法
|
|
WO2018049417A1
(en)
|
2016-09-12 |
2018-03-15 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
MX390582B
(es)
|
2016-12-28 |
2025-03-20 |
Dart Neuroscience Llc Star |
Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2)
|
|
ES2902365T3
(es)
|
2017-11-27 |
2022-03-28 |
Dart Neuroscience Llc |
Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
|
|
EP3746081A4
(en)
|
2018-01-31 |
2021-10-27 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
EP4025202A4
(en)
|
2019-09-03 |
2023-08-02 |
Intra-Cellular Therapies, Inc. |
NOVEL CONNECTIONS
|
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|